NCT00820326View on ClinicalTrials.gov

Efficacy of Dolasetron in Patients With Fibromyalgia

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Fibromyalgia
Interventions
DRUG

Dolasetron

Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3

DRUG

Placebo

Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3

Trial Locations (1)

87000

Service de Rhumatologie, CHu de Limoges, Limoges

All Listed Sponsors
lead

University Hospital, Limoges

OTHER

NCT00820326 - Efficacy of Dolasetron in Patients With Fibromyalgia | Biotech Hunter | Biotech Hunter